Related Experiment Video
Updated: Dec 30, 2025
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.3K
Small molecule biomarkers for neonatal hypoxic ischemic encephalopathy
Ángel Sánchez-Illana1, José David Piñeiro-Ramos1, Julia Kuligowski1
1Health Research Institute La Fe, Avda. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Seminars in Fetal & Neonatal Medicine
|January 28, 2020
Summary
Hypoxic Ischemic Encephalopathy (HIE) biomarkers are crucial for personalized therapies. This review explores metabolomics approaches for discovering and translating these small molecule biomarkers into clinical practice.
Area of Science:
- Biochemistry
- Perinatal Medicine
- Biomarker Discovery
Background:
- Hypoxic Ischemic Encephalopathy (HIE) is a severe perinatal condition.
- Accurate diagnosis, staging, and prognosis are vital for personalized HIE therapies.
- Small molecule biomarkers are needed for improved clinical management.
Purpose of the Study:
- To review current approaches for discovering HIE-related small molecule biomarkers.
- To discuss the role of these biomarkers in HIE pathogenesis.
- To examine the translation of biomarkers into clinical practice.
Main Methods:
- Systematic review of metabolomics studies for HIE biomarker discovery.
- Analysis of different analytical platforms, animal models, and human populations.
- Evaluation of biochemical pathways implicated in HIE.
Main Results:
- Metabolomics has significantly expanded the pool of candidate HIE biomarkers.
- Numerous small molecules have been identified across diverse studies.
- Limited translation of identified biomarkers into clinical guidelines or devices.
Conclusions:
- Metabolomics offers powerful tools for HIE biomarker discovery.
- Understanding biomarker roles in disease mechanisms is key.
- Overcoming translation challenges is essential for clinical implementation.
